ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2022
Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer.
Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Evaluation of sarcopenia and myosteatosis to determine the impact on mortality after emergency laparotomy.BJS open · 2025Article
- Sarcopenia diagnosed by computed tomography predicts postoperative complications in advanced epithelial ovarian cancer.Aging clinical and experimental research · 2024Article
- The association of body composition phenotypes before chemotherapy with epithelial ovarian cancer mortality.Journal of the National Cancer Institute · 2024Article
- Predictive Value of a New Muscle Parameter in Patients with Resectable Gastric Cancer: A Pooled Analysis of Three Prospective Trials.Annals of surgical oncology · 2024Article
- Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia.Current oncology (Toronto, Ont.) · 2023Article
- Association of malignant ascites with systemic inflammation and muscle loss after treatment in advanced-stage ovarian cancer.Journal of cachexia, sarcopenia and muscle · 2023Article
- Explainable machine learning model for predicting skeletal muscle loss during surgery and adjuvant chemotherapy in ovarian cancer.Journal of cachexia, sarcopenia and muscle · 2023Article
- Muscle loss during cancer therapy is associated with poor outcomes in advanced ovarian cancer.Journal of the National Cancer Institute. Monographs · 2023Article
- Correspondence on "Quality is more important than quantity: pre-operative sarcopenia is associated with poor survival in advanced ovarian cancer" by Polen-De et al.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2022Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundSarcopenia is prevalent among older patients with cancer and is associated with poor outcomes.
objectiveTo explore the relationship between muscle mass, quality, and patient age with overall survival after surgery for advanced ovarian cancer.
methodsPatients with advanced stage (IIIC/IV) ovarian cancer who underwent primary cytoreductive surgery between January 2006 and July 2016 were included. Body composition measures were calculated from pre-operative CT imaging: skeletal muscle index (skeletal muscle index=skeletal muscle area normalized for height), skeletal muscle density, and skeletal muscle gauge (product of skeletal muscle index and skeletal muscle density). Each measure was transformed to a z-score and evaluated for association with risk of death using Cox proportional hazards models. Recursive partitioning was used to classify patients into homogeneous subgroups considering age and skeletal muscle gauge as predictors of overall survival.
resultsThe study included 429 patients (mean age 64.2 years). Increased age moderately correlated with decreased skeletal muscle gauge (r=-0.45). Decreasing skeletal muscle density and skeletal muscle gauge were significantly associated with increased risk of death; HR (95% CI) per 1-unit decrease in z-score of 1.24 (1.10 to 1.39) for skeletal muscle density and 1.27 (1.12 to 1.44) for skeletal muscle gauge. Associations were diluted after adjusting for age (1.13 (1.00 to 1.29) skeletal muscle density and 1.14 (0.99 to 1.30) skeletal muscle gauge). Recursive partitioning identified three subgroups: <60 years old, ≥60 years old with skeletal muscle gauge ≥937.3, and ≥60 years old with skeletal muscle gauge <937.3; median overall survival was 5.8, 3.3, and 2.3 years, respectively (p<0.001).
conclusionsSkeletal muscle gauge, a novel sarcopenia measure incorporating quantity and quality, was associated with poorer survival in patients with advanced ovarian cancer, particularly among patients older than 60. Expanding our knowledge of how sarcopenia relates to solid tumor outcomes among high-risk patients can modify our treatment approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.